Previous 10 | Next 10 |
Speaking during a House Ways and Means Committee bill markup Wednesday, Rep. Earl Blumenauer (D-Ore.) said that psychedelic drugs have "real potential" as mental health therapies with "less impact" than prescription drugs. "Oregon is involved in an experiment with therapeutic psilocyb...
FN Media Group Presents Microsmallcap.com Market Commentary New York, NY – September 22, 2022 – Atlanta just became the latest city to consider decriminalizing psychedelics. On September 12, just one week after San Francisco officially decriminali...
MindMed ( NASDAQ: MNMD ) has dosed the first patient in a phase 1 trial that will examine the effect of substances containing the psychedlic MDMA , a potential treatment for mental illnesses. The purpose of the trial in healthy volunteers is to measure pharmacokinetics...
MindMed Collaborators Dose First Patient in Phase 1 Investigator-Initiated Trial of MDMA-Like Substances Canada NewsWire First-in-human trial to investigate the tolerability, pharmacology, and pharmacokinetics of novel MDMA-like compounds versus a placebo in heal...
Right now, analysts up and down Wall Street are pounding the table on a little-known biotech company called MindMed (NASDAQ: MNMD) . Based on the price targets they've set, the average analyst thinks it can rise around 543% from its recent price of around $8 per share. So is now...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Source: iQoncept/ShutterStock.com CF Acquisition (NASDAQ: CFVI ) stock is getting a boost on Wednesday as investors prepare to vote on a SPAC merger tomorrow. CF Acquisition will hold a special shareholder m...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Source: CI Photos / Shutterstock.com BioAffinity (NASDAQ: BIAF ) stock is rising higher on Wednesday after the cancer diagnostic company announced the publication of its research in PLOS ONE . This was publ...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Source: Daniel Patrick Martin / Shutterstock.com MindMed (NASDAQ: MNMD ) stock is in the news Wednesday after the psychedelic medicine company regained Nasdaq compliance. According to a press release from t...
Mind Medicine ( OTC:MMED ) has received Nasdaq notification that it has regained compliance with Nasdaq's minimum bid price listing requirement. The company believes the completion of the reverse share split and subsequent attainment of compliance with Nasdaq listing require...
MindMed Announces Compliance with Nasdaq Listing Requirements Canada NewsWire NEW YORK , Sept. 14, 2022 /CNW/ -- Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (the "Company" or "MindMed"), a clinical stage biopharmaceutical company developing ...
News, Short Squeeze, Breakout and More Instantly...
Mind Medicine (MindMed) Inc. Company Name:
MNMD Stock Symbol:
NASDAQ Market:
Mind Medicine (MindMed) Inc. Website:
2024-07-26 17:46:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
- New patent covers MM120 ODT formulation and extends patent term to 2041- - Claims include pharmaceutical formulation, methods of manufacturing and methods of treatment for MM120 ODT- Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (the “Company” or “MindMed...
Cluster headaches are headaches characterized by severe pain that often occurs on a side of the head or behind one eye. These headaches may last anywhere between 15 minutes to 3 hours and usually strike suddenly, often recurring more than once a day. The pain experienced by patients is... R...